Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Beam Therapeutics Inc stock

Learn how to easily invest in Beam Therapeutics Inc stock.

Beam Therapeutics Inc is a biotechnology business based in the US. Beam Therapeutics Inc shares (BEAM) are listed on the NASDAQ and all prices are listed in US Dollars. Beam Therapeutics Inc employs 394 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Beam Therapeutics Inc

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BEAM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Beam Therapeutics Inc stock price (NASDAQ: BEAM)

Use our graph to track the performance of BEAM stocks over time.

Beam Therapeutics Inc shares at a glance

Information last updated 2022-07-02.
Latest market close$39.79
52-week range$27.77 - $129.50
50-day moving average $36.72
200-day moving average $65.47
Wall St. target price$89.55
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-3.59

Buy Beam Therapeutics Inc shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Beam Therapeutics Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Beam Therapeutics Inc price performance over time

Historical closes compared with the close of $39.79 from 2022-07-01

1 week (2022-06-28) -1.51%
1 month (2022-06-01) 16.93%
3 months (2022-04-05) -29.51%
6 months (2022-01-01) N/A
1 year (2021-07-02) -69.44%
2 years (2020-07-02) 37.82%
3 years (2019-07-01) N/A
5 years (2017-07-01) N/A

Beam Therapeutics Inc financials

Revenue TTM $60.3 million
Gross profit TTM $-180,290,000
Return on assets TTM -6.6%
Return on equity TTM -38.08%
Profit margin 0%
Book value $12.16
Market capitalisation $2.8 billion

TTM: trailing 12 months

Beam Therapeutics Inc share dividends

We're not expecting Beam Therapeutics Inc to pay a dividend over the next 12 months.

Beam Therapeutics Inc share price volatility

Over the last 12 months, Beam Therapeutics Inc's shares have ranged in value from as little as $27.77 up to $129.5. A popular way to gauge a stock's volatility is its "beta".

BEAM.US volatility(beta: 1.6)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Beam Therapeutics Inc's is 1.6025. This would suggest that Beam Therapeutics Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Beam Therapeutics Inc overview

Beam Therapeutics Inc. , a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc. ; license agreement with Sana Biotechnology, Inc. ; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel.

Frequently asked questions

What percentage of Beam Therapeutics Inc is owned by insiders or institutions?
Currently 1.989% of Beam Therapeutics Inc shares are held by insiders and 79.792% by institutions.
How many people work for Beam Therapeutics Inc?
Latest data suggests 394 work at Beam Therapeutics Inc.
When does the fiscal year end for Beam Therapeutics Inc?
Beam Therapeutics Inc's fiscal year ends in December.
Where is Beam Therapeutics Inc based?
Beam Therapeutics Inc's address is: 238 Main Street, Cambridge, MA, United States, 02142
What is Beam Therapeutics Inc's ISIN number?
Beam Therapeutics Inc's international securities identification number is: US07373V1052

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site